Form: CORRESP

A correspondence can be sent as a document with another submission type or can be sent as a separate submission.

December 18, 2015

 

 

 

Seaport West
155 Seaport Boulevard
Boston, MA 02210-2600

 

617 832 1000 main

617 832 7000 fax

December 18, 2015  
VIA EDGAR

 

Securities and Exchange Commission

Division of Corporate Finance

100 F Street, N.E.

Washington, DC 20549

 

   
  Re:

Cellectar Biosciences, Inc. (CIK 0001279704)

Registration Statement on Form S-1

         

Ladies and Gentlemen:

This letter constitutes supplemental correspondence on behalf of Cellectar Biosciences, Inc., a Delaware corporation (the “Company”), related to and filed together with the Company’s Registration Statement on Form S-1 (the “Registration Statement”). The Registration Statement covers the issuance and sale by the Company of shares of the Company’s common stock, $0.00001 par value per share (“Common Stock”), and warrants to purchase shares of Common Stock (the “Warrants”), together in an underwritten offering intended to raise $10,000,000.

Please direct any communications concerning the Registration Statement to the undersigned at (617) 832-1113, email—pbork@foleyhoag.com, or, in my absence, Daniel Clevenger at (617) 832-1283, email—dclevenger@foleyhoag.com. The email address of the Company’s agent for service is jcaruso@cellectar.com.

 

  Very truly yours,  
     
     
  /s/ Paul Bork  
    Paul Bork  

  

cc: Daniel Clevenger, Esq.

 

 

 

ATTORNEYS AT LAW BOSTON   |   NEW YORK   |   PARIS   |   WASHINGTON   |   FOLEYHOAG.COM